MAIN CONTENT
A higher offer, but with conditions
The revised arrangement sets a $25 cash price for Surgery Partners shareholders other than affiliates of Bain Capital. That compares with the $23.50 announced in the earlier agreement. It is an improvement of $1.50 per share, but it does not mean every shareholder will automatically receive the maximum figure cited in the headline. The larger number depends on when the deal closes and on conditions spelled out in the amended contract.
If the necessary shareholder approval has been obtained and completion occurs after March 1, 2027, eligible holders may receive an additional monthly cash payment. At the final contractual outside date of October 23, 2027, those payments could total $1.61 a share, bringing proceeds to $26.61. The $6 billion figure refers to potential enterprise value, which is distinct from simply multiplying the stock price by shares outstanding. The parties currently anticipate closing in the first quarter of 2027, meaning the extra payments are not guaranteed.
Why the $28 rival bid did not prevail
An unsolicited buyer approached Surgery Partners on November 3 and subsequently advanced a nonbinding offer of $28 a share. The headline price exceeded HealthSpan's immediate cash consideration and also its highest potential delayed-closing payout.















